Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Pharma’s digital directions in 2014

Multi-channel marketing a priority, but mobile websites may be neglected

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

China flag thumb

Actavis divests another Chinese interest

Reduces presence in “risky” market

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

ASA bans two Botox ads

Dermaskin Clinics and HB Health forced to remove promotions from website homepages

- PMLiVE

Janssen announces new group to tackle global health

Will implement R&D and access strategies to support areas with unmet public health need

- PMLiVE

Merck KGaA loses CFO to Lanxess

Matthias Zachert joins chemical company as CEO

- PMLiVE

Open Road boosts healthcare offering

Communications specialist hires senior consultant for its healthcare team

- PMLiVE

Taking contract research’s pulse

The last 12 months have seen the cost-cutting drive sweeping through the pharma industry move beyond sales, administration and manufacturing and start to affect R&D

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

- PMLiVE

Otsuka/Lundbeck say brexpiprazole works in phase III trial

On course as successor to antipsychotic Abilify

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links